BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2959717)

  • 1. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
    de Bono DP
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
    Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
    J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.
    de Bono DP
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):20A-23A. PubMed ID: 2973485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
    Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
    Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
    J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Rothbaum D; Candela RJ; Abbotsmith CW; Pinkerton CA; Stump DC; Collen D
    Circulation; 1988 May; 77(5):1100-7. PubMed ID: 2966017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
    Magnani B
    J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
    Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
    J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
    White HD; Rivers JT; Maslowski AH; Ormiston JA; Takayama M; Hart HH; Sharpe DN; Whitlock RM; Norris RM
    N Engl J Med; 1989 Mar; 320(13):817-21. PubMed ID: 2494454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
    Jorge Sdo C
    Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.
    Topol EJ; Morris DC; Smalling RW; Schumacher RR; Taylor CR; Nishikawa A; Liberman HA; Collen D; Tufte ME; Grossbard EB
    J Am Coll Cardiol; 1987 Jun; 9(6):1205-13. PubMed ID: 2953770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
    Sherry S; Marder VJ
    Ann Intern Med; 1991 Mar; 114(5):417-23. PubMed ID: 1899546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
    Van de Werf F
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):14A-19A. PubMed ID: 3142943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.